Suggested remit: To appraise the clinical and cost effectiveness of ticagrelor within its marketing authorisation for preventing stroke after previous acute ischaemic stroke or high-risk transient ischaemic attack.
 
Status In progress
Process STA 2018
ID number 2689

Provisional Schedule

Expected publication 01 June 2022

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
05 January 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of ticagrelor within its marketing authorisation for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-July 2021. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
03 September 2020 In progress. Topic is in progress
03 September 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of ticagrelor within its marketing authorisation for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early January 2021. These timings are based on a three month delay request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
11 June 2020 - 09 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance